Terminated
PHASE3
INTERVENTIONAL
NCT00415246
Study to Evaluate a Subcutaneous Four Months Sustained-release Formulation of Triptorelin in Patients With Prostate Cancer
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
To identify the proportion of patients remaining medically castrated (testosterone level \< 50 ng/dL) on Day 240 following two administrations of a 4-month sustained-release (SR) formulation of triptorelin.
Interventions
Name:
Triptorelin (Decapeptyl®) - Treatment 8 months (pivotal study) followed by a treatment extension of 8 months (extension study)
Type:
DRUG
Description:
Primary Outcomes
Measure:
Proportion of patients with testosterone serum levels maintained below the castration threshold of 50 ng/dL.
TimeFrame:
Day 240
Description:
Trial Information
NCT ID
NCT00415246
Status
Terminated
Study Type
INTERVENTIONAL
Phases
PHASE3
Sponsor
Ipsen
Last Updated
December 15, 2025